Clinical Quick Reference Guides

Playback speed

Share post at current time

Share from 0:00

0:00

Clinical Quick Reference Guides - April 2023 News

Clinical Quick Take On New Anti-Amyloid Alzheimer's Disease Therapies

Beth Kirsch, MA, BSN, RN

Apr 10, 2023

A systematic review and MRI data analysis reveal anti-amyloid therapies for Alzheimer's disease may actually accelerate brain atrophy.

Learn more about the research and findings here:

https://www.medpagetoday.com/neurology/alzheimersdisease/103817

Share Clinical Quick Reference Monthly

Resources:

Alves F, et al "Accelerated brain volume loss caused by anti-β-amyloid drugs: A systematic review and meta-analysis" Neurology 2023

Barkhof F, Knopman DS "Brain shrinkage in anti-β-amyloid Alzheimer trials: Neurodegeneration or pseudo-atrophy?" Neurology 2023

Learn more about monoclonal antibodies here:

Clinical Quick Reference Monthly

What is mAb?

Why Does My Patient's Medication End In "-mab?" In 2019, there were seven biosimilar medications on the market in the United States and 18 more had been approved by the FDA (Food and Drug Administration). It was clear that such advanced biologic therapeutics were to become a prominent force in medicine and the healthcare marketplace…

3 years ago · 14 likes · Beth Kirsch RN, BSN

This study guide resource regarding specific medications is not intended to be used as medical advice. Note that products used tend to vary from institution to institution. Always pursue and follow the advise of your healthcare provider, facility protocols or supervising agency in matters of health issues or problems. Call 911 in case of acute emergency.